Interface Biologics Completes $7M Series B Financing
Summary
Interface Biologics, Inc., a Toronto, Canada-based commercial stage developer of innovative biomedical-polymer products, completed a $7m Series B financing., a Toronto, Canada-based commercial stage developer of innovative biomedical-polymer products, completed a $7m The round was led by Business Development Bank of Canada, with participation from Covington Capital and VG Partners.As stated by Tom Reeves, President & CEO of Interface Biologics, this financing will allow the company to reach cash flow breakeven.Interface Biologics, which is a University of Toronto spinoff, develops biomedical polymer technology to improve the safety and effectiveness of medical devices.The company, which is now located at the MaRS Centre in Toronto, is trying to raise additional $3-5m in funding to facilitate development of other applications.
Funding
Review available funding amount, funding date, investors, and linked company information related to Interface Biologics Completes $7M Series B Financing in the interactive ISVWorld profile.